$IMUX
Immunic Inc

2024 Q3 Form 10-Q Financial Statement

#000128077624000014 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.491M
YoY Change 16.68%
% of Gross Profit
Research & Development $18.32M
YoY Change -13.46%
% of Gross Profit
Depreciation & Amortization $31.00K
YoY Change 40.91%
% of Gross Profit
Operating Expenses $22.81M
YoY Change -8.82%
Operating Profit -$22.81M
YoY Change -8.82%
Interest Expense $998.0K
YoY Change 3.1%
% of Operating Profit
Other Income/Expense, Net $1.434M
YoY Change 2555.56%
Pretax Income -$21.38M
YoY Change -10.91%
Income Tax
% Of Pretax Income
Net Earnings -$21.38M
YoY Change -10.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$0.21
COMMON SHARES
Basic Shares Outstanding 90.08M shares 90.08M shares
Diluted Shares Outstanding 101.3M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.70M
YoY Change 3.11%
Cash & Equivalents $79.70M
Short-Term Investments
Other Short-Term Assets $1.057M
YoY Change -86.91%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $84.98M
YoY Change -1.82%
LONG-TERM ASSETS
Property, Plant & Equipment $585.0K
YoY Change -72.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.513M
YoY Change -30.85%
TOTAL ASSETS
Total Short-Term Assets $84.98M
Total Long-Term Assets $1.513M
Total Assets $86.49M
YoY Change -2.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.894M
YoY Change 67.96%
Accrued Expenses $13.78M
YoY Change 3.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.68M
YoY Change 24.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $241.0K
YoY Change -80.15%
Total Long-Term Liabilities $241.0K
YoY Change -80.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.68M
Total Long-Term Liabilities $241.0K
Total Liabilities $22.92M
YoY Change 17.8%
SHAREHOLDERS EQUITY
Retained Earnings -$461.9M
YoY Change 26.0%
Common Stock $8.000K
YoY Change 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.57M
YoY Change
Total Liabilities & Shareholders Equity $86.49M
YoY Change -2.53%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$21.38M
YoY Change -10.91%
Depreciation, Depletion And Amortization $31.00K
YoY Change 40.91%
Cash From Operating Activities -$17.03M
YoY Change -14.74%
INVESTING ACTIVITIES
Capital Expenditures $180.0K
YoY Change 757.14%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$180.0K
YoY Change -104.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -17.03M
Cash From Investing Activities -180.0K
Cash From Financing Activities 0.000
Net Change In Cash -17.21M
YoY Change 10.72%
FREE CASH FLOW
Cash From Operating Activities -$17.03M
Capital Expenditures $180.0K
Free Cash Flow -$17.21M
YoY Change -13.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Entity Registrant Name
EntityRegistrantName
Immunic, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
332
dei Local Phone Number
LocalPhoneNumber
255-9818
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
IMUX
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
90079016 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79698000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46674000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
436000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1658000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1233000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1434000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1022000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4269000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3001000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23999000 usd
us-gaap Net Income Loss
NetIncomeLoss
-50964000 usd
us-gaap Net Income Loss
NetIncomeLoss
-49271000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101272580 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101272580 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99607158 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99607158 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21380000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23999000 usd
us-gaap Net Income Loss
NetIncomeLoss
-50964000 usd
us-gaap Net Income Loss
NetIncomeLoss
-49271000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-505000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
171000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
23000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
947000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21885000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23828000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2977000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4420000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
211000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-211000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
191000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74464000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-229000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33024000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46674000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106745000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79698000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5860000 usd
CY2023Q4 vtl Clinical Costs Payable Current
ClinicalCostsPayableCurrent
4726000 usd
vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
527000 usd
vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
434000 usd
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line1
EntityAddressAddressLine1
1200 Avenue of the Americas
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21380000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
69284000 usd
us-gaap Net Income Loss
NetIncomeLoss
-49271000 usd
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5280000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5860000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
84978000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
52534000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1299000 usd
CY2024Q2 us-gaap Assets
Assets
86491000 usd
CY2023Q4 us-gaap Assets
Assets
54299000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7894000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5099000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13775000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18664000 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1008000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
966000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22677000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
639000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
241000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
639000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
22918000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
25368000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
8000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
521639000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-461856000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
63573000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
28931000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
86491000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54299000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18323000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21172000 usd
us-gaap Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration
GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense
us-gaap Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration
GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense
dei Entity File Number
EntityFileNumber
001-36201
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2358443
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
585000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
466000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
928000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24729000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
241000 usd
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90079016 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90079016 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45177730 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45177730 shares
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
436060000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3782000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3759000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410892000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37059000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44135000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4491000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3849000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9636000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8137000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
22814000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
25021000 usd
us-gaap Operating Expenses
OperatingExpenses
46695000 usd
us-gaap Operating Expenses
OperatingExpenses
52272000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22814000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25021000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-46695000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-52272000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
998000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
968000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2185000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1768000 usd
CY2024Q2 vtl Fair Value Change In Fair Value Of Tranche Rights Transaction Costs
FairValueChangeInFairValueOfTrancheRightsTransactionCosts
0 usd
CY2023Q2 vtl Fair Value Change In Fair Value Of Tranche Rights Transaction Costs
FairValueChangeInFairValueOfTrancheRightsTransactionCosts
0 usd
vtl Fair Value Change In Fair Value Of Tranche Rights Transaction Costs
FairValueChangeInFairValueOfTrancheRightsTransactionCosts
4796000 usd
vtl Fair Value Change In Fair Value Of Tranche Rights Transaction Costs
FairValueChangeInFairValueOfTrancheRightsTransactionCosts
0 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44432955 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44432955 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44036352 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44036352 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50941000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48324000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
28931000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-29584000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2750000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
528000 usd
CY2024Q1 vtl Adjustments To Additional Paid In Capital Conversion Of Tranche Rights Liability To Equity
AdjustmentsToAdditionalPaidInCapitalConversionOfTrancheRightsLiabilityToEquity
28396000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
83576000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21380000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1882000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-505000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
63573000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
113684000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25272000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1979000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
776000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
51000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
91218000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23999000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1798000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
171000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
96000 usd
us-gaap Net Income Loss
NetIncomeLoss
-50964000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
57000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
147000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-665000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4632000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3777000 usd
vtl Change In Fair Value Of Tranche Rights
ChangeInFairValueOfTrancheRights
4796000 usd
vtl Change In Fair Value Of Tranche Rights
ChangeInFairValueOfTrancheRights
0 usd
us-gaap Management Fee Expense
ManagementFeeExpense
1690000 usd
us-gaap Management Fee Expense
ManagementFeeExpense
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-375000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-312000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
449000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4462000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
63000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39489000 usd
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
0 usd
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-9796000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9671000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
74273000 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
96000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
51000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
147000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29451000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77294000 usd
vtl Conversion Of Tranche Rights Liability To Equity Upon Increase In Authorized Shares
ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares
28396000 usd
vtl Conversion Of Tranche Rights Liability To Equity Upon Increase In Authorized Shares
ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
544000 usd
CY2024Q2 vtl Number Of Development Programs
NumberOfDevelopmentPrograms
3 lease
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-461900000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410900000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
430900000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79700000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to clinical trial expenses and stock-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div>
CY2024Q2 vtl Number Of Financial Institutions Used For Cash Deposit
NumberOfFinancialInstitutionsUsedForCashDeposit
2 financialinstitution
CY2024Q2 us-gaap Depreciation
Depreciation
31000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
22000 usd
us-gaap Depreciation
Depreciation
57000 usd
us-gaap Depreciation
Depreciation
54000 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2024Q2 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
3000 usd
CY2023Q2 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
301000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
39000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
2100000 usd
CY2024Q2 vtl Lessee Operating Leases Number Of Existing Leases
LesseeOperatingLeasesNumberOfExistingLeases
3 lease
CY2024Q2 vtl Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
2221000 usd
CY2023Q4 vtl Prepaid Clinical And Related Costs Current
PrepaidClinicalAndRelatedCostsCurrent
2314000 usd
CY2024Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
806000 usd
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
703000 usd
CY2024Q2 vtl Government Assistance Qualified Research And Development Expenditures Maximum Amount
GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount
696000 usd
CY2023Q4 vtl Government Assistance Qualified Research And Development Expenditures Maximum Amount
GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount
670000 usd
CY2024Q2 vtl Research And Development Grant
ResearchAndDevelopmentGrant
0 usd
CY2023Q4 vtl Research And Development Grant
ResearchAndDevelopmentGrant
1104000 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
500000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
198000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1057000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
871000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5280000 usd
CY2024Q2 vtl Clinical Costs Payable Current
ClinicalCostsPayableCurrent
7605000 usd
CY2024Q2 vtl Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
13000 usd
CY2023Q4 vtl Legal And Audit Costs Payable Current
LegalAndAuditCostsPayableCurrent
160000 usd
CY2024Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
276000 usd
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
213000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7894000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5099000 usd
CY2024Q2 vtl Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
12368000 usd
CY2023Q4 vtl Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
16863000 usd
CY2024Q2 vtl Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
201000 usd
CY2023Q4 vtl Accrued Legal And Audit Costs Current
AccruedLegalAndAuditCostsCurrent
216000 usd
CY2024Q2 vtl Accrued Compensation Current
AccruedCompensationCurrent
996000 usd
CY2023Q4 vtl Accrued Compensation Current
AccruedCompensationCurrent
1460000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
125000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13775000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18664000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
714000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
695000 usd
CY2024Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
294000 usd
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
271000 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1008000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
966000 usd
CY2024Q2 vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
270000 usd
CY2023Q2 vtl Operating And Variable Leases Cost
OperatingAndVariableLeasesCost
238000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
346000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
433000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
78000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
82000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
79000 usd
CY2024Q2 vtl Lessee Operating Lease Liability Payments After Due Year Four
LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour
0 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1018000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
955000 usd
CY2024Q2 us-gaap Contractual Obligation
ContractualObligation
1800000 usd
CY2024Q1 vtl Tranche Right Fair Value Disclosure
TrancheRightFairValueDisclosure
23600000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 vtl Fair Value Reclassification Of Future Tranche Right Liability Upon Settlement
FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement
4800000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
23600 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
4796 usd
vtl Reclassification To Equity
ReclassificationToEquity
-28396 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2023Q4 vtl Maximum Aggregate Offering Price Of Securities Under Shelf Registration
MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
250000000 usd
CY2024Q2 vtl Unsold Securities Rolled Over To Be Sold Under New Shelf Registration
UnsoldSecuritiesRolledOverToBeSoldUnderNewShelfRegistration
412300000 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 vtl Number Of Votes Per Each Share Of Common Stock
NumberOfVotesPerEachShareOfCommonStock
1 numberofvote
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
124929746 shares
CY2024Q1 vtl Share Based Compensation By Share Based Payment Award Options Repriced Number Of Shares
ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares
3317596 shares
CY2024Q1 vtl Share Based Payment Arrangement Plan Modification Option Exercise Price
ShareBasedPaymentArrangementPlanModificationOptionExercisePrice
1.72
CY2024Q1 vtl Share Based Compensation By Share Based Payment Award Options Repriced Amortization Cost Over Remaining Term
ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedAmortizationCostOverRemainingTerm
1200000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
17000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
1000000 usd
vtl Share Based Compensation Arrangement By Share Based Payment Award Options Repricing Modification In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod
0 shares
vtl Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Repricing Modifications Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice
9.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001280776-24-000014-index-headers.html Edgar Link pending
0001280776-24-000014-index.html Edgar Link pending
0001280776-24-000014.txt Edgar Link pending
0001280776-24-000014-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
immunic-jasontardioemplo.htm Edgar Link pending
immunic-jasontardioemplo001.jpg Edgar Link pending
immunic-jasontardioemplo002.jpg Edgar Link pending
immunic-jasontardioemplo003.jpg Edgar Link pending
immunic-jasontardioemplo004.jpg Edgar Link pending
immunic-jasontardioemplo005.jpg Edgar Link pending
immunic-jasontardioemplo006.jpg Edgar Link pending
immunic-jasontardioemplo007.jpg Edgar Link pending
immunic-jasontardioemplo008.jpg Edgar Link pending
immunic-jasontardioemplo009.jpg Edgar Link pending
immunic-jasontardioemplo010.jpg Edgar Link pending
immunic-jasontardioemplo011.jpg Edgar Link pending
immunic-jasontardioemplo012.jpg Edgar Link pending
immunic-jasontardioemplo013.jpg Edgar Link pending
immunic-jasontardioemplo014.jpg Edgar Link pending
immunic-jasontardioemplo015.jpg Edgar Link pending
immunic-jasontardioemplo016.jpg Edgar Link pending
immunic-jasontardioemplo017.jpg Edgar Link pending
immunic-jasontardioemplo018.jpg Edgar Link pending
imux-63024xexhibit311.htm Edgar Link pending
imux-63024xexhibit312.htm Edgar Link pending
imux-63024xexhibit322.htm Edgar Link pending
imux-630x24xexhibit321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-20240630.htm Edgar Link pending
vtl-20240630.xsd Edgar Link pending
vtl-20240630_g1.jpg Edgar Link pending
vtl-20240630_def.xml Edgar Link unprocessable
vtl-20240630_pre.xml Edgar Link unprocessable
vtl-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
vtl-20240630_cal.xml Edgar Link unprocessable
vtl-20240630_lab.xml Edgar Link unprocessable